Design of the OverCool study: Lung-conservative liquid ventilation for the induction of Ultra-Rapid Cooling after Cardiac Arrest (OverCool)

OverCool 研究设计:心脏骤停后采用肺部保守液体通气诱导超快速降温 (OverCool)

阅读:1

Abstract

BACKGROUND: The therapeutic window within which induced hypothermia might be effective after cardiac arrest is still unknown. In animal cardiac arrest models, early induction and faster cooling are independently associated favorable outcome. However, induction of Ultra-Rapid Therapeutic Hypothermia (achieving core body temperature of 33.0 ± 0.5 °C within 60 min after the start of the procedure) still need to be evaluated in the human setting. Total liquid ventilation with temperature-controlled breathable liquids provided such rapid cooling (i.e. >15 °C/h cooling rate) in both small and large animals. This method was shown to improve neurological outcome in animals. A new medical device system, Vent2Cool, was developed for clinical use in the Intensive Care Unit to achieve ultra-rapid therapeutic hypothermia by total liquid ventilation to patients. MATERIALS AND METHODS: The non-blinded and single-arm OverCool pilot trial will evaluate the feasibility, cooling performance and safety of ultra-rapid therapeutic hypothermia by total liquid ventilation in 24 patients resuscitated after in- or out-of-hospital cardiac arrest. Inclusion criteria will include presumption to start ultra-rapid cooling procedure in the Intensive Care Unit within less than 120 min after resuscitation. The primary outcome will be the achievement of a core temperature of 33.0 ± 0.5 °C, as well as successful return to conventional gas ventilation within <60 min after procedure initiation. Secondary outcomes will include time to reach target temperature, vital status, systemic and pulmonary parameters and modified-Rankin Score at 28 days post- cardiac arrest. CONCLUSION: The OverCool study is a pilot study to validate performance and safety of ultra-rapid therapeutic hypothermia using total liquid ventilation for resuscitated cardiac arrest patients. REGISTRATION AND AUTHORIZATION: NCT06798818. Authorized by the French "Agence nationale de sécurité du médicament et des produits de santé" and "Comité de Protection des Personnes" (Ethics Committee).

特别声明

1、本页面内容包含部分的内容是基于公开信息的合理引用;引用内容仅为补充信息,不代表本站立场。

2、若认为本页面引用内容涉及侵权,请及时与本站联系,我们将第一时间处理。

3、其他媒体/个人如需使用本页面原创内容,需注明“来源:[生知库]”并获得授权;使用引用内容的,需自行联系原作者获得许可。

4、投稿及合作请联系:info@biocloudy.com。